Finally, recent clinical trials underscore that new classes of glucose-lowering agents, such as the GLP1 receptor agonists and related targets, and the SGLT2 inhibitors, impart significant cardioprotective (and renoprotective) effects in T2D. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.